TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01719419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
Study: NCT02002793

Intervention type: OTHER
Group type: OTHER
Intervention: Early stage abdominal drainage
Description: Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;

Intervention type: OTHER
Group type: OTHER
Intervention: Late stage abdominal drainage
Description: Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
Study: NCT02195154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study: NCT02673073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's diary
Description: Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient's education
Description: All patients will receive patient's information/education booklet on the heart failure including life style modification.
Study: NCT02307461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145 (duvelisib)
Description: High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
Study: NCT01086488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSCAN
Description: Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
Study: NCT02307461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
Study: NCT03386110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Health Project (CHP)
Description: The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
Study: NCT00312923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Policosanol
Description: 20 mg of policosanol in capsular form daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of 10 mg of microcrystalline cellulose daily
Study: NCT03636477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: * 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veledimex
Description: * 2 doses (10mg/day, 20mg/day)~* 15 oral daily doses of veledimex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * 2 doses (1mg/kg, 3mg/kg)~* Every 2 weeks
Study: NCT01887886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onartuzumab
Description: 15 mg/kg IV every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV every 3 weeks
Study: NCT02531945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Biomod device
Study: NCT02355990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy
Description: Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
Study: NCT02078908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite, 40 micrograms/kg/hour
Description: Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite, 120 micrograms/kg/hour
Description: Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
Study: NCT04213261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Description: FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
Study: NCT02078908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite, 240 micrograms/kg/hour
Description: Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous 2 hour infusion of sodium chloride, 25 ml/hour
Study: NCT02858843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumacaftor-ivacaftor
Description: Drug given for cystic fibrosis
Study: NCT04013568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students~Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes
Study: NCT00760474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin, then placebo
Description: Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, then pregabalin
Description: Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
Study: NCT03723252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin 10mg po qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo po qd
Study: NCT03148444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefalexin 500 mg qid or roxithromycin 150 mg bid
Description: antibiotics treatment for five days following implantation of cardiac device
Study: NCT02794922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurovit Forte

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corn Starch
Study: NCT03532763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction
Description: 1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
Study: NCT01725789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject®
Description: Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .~Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight \<50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value \<15ng/mL and Hb\<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
Study: NCT03965351

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probenecid
Description: This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT03456427

Intervention type: DEVICE
Group type: OTHER
Intervention: Patient-Assisted Compression (PAC)
Description: The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) \& Mediolateral Oblique (MLO).

Intervention type: DEVICE
Group type: OTHER
Intervention: Technologist-Controlled (TC) Compression
Description: TC compression will be conducted per standard of care practices at the site.
Study: NCT02232243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 200mg twice dailiy
Description: Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 200mg twice dailiy
Description: Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 400mg twice daily
Description: Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
Study: NCT04322877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary pacing Study
Description: Temporary delivery of CRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary pacing Study
Description: Temporary delivery of CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic CT
Description: As part of non-invasive mapping protocol

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute hemodynamic study
Description: Measurement of invasive dP/dTmax

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute hemodynamic study
Description: Measurement of invasive dP/dTmax

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive body surface mapping
Description: Cardioinsight body surface mapping

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive catheter-based mapping
Description: Invasive electroanatomical mapping
Study: NCT01305200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supersaturated calcium phosphate rinse
Description: Mouth rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Mouth rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04415983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Klacid twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Klacid twice daily
Study: NCT03532763

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
Study: NCT02908334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 400 mg/day sertraline
Study: NCT04415983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Description: Omeprazoe twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor
Description: Omeprazoe twice daily
Study: NCT04524026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg
Description: recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
Study: NCT01534572

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Description: Intervention (2 weeks) with a strain of Lactobacillus

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Description: Intervention (2 weeks) with a strain of Bifidobacterium
Study: NCT01027832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam for 7 days
Description: Piperacillin/Tazobactam for 7 days
Study: NCT03427853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY06006
Description: LY06006 18mg, 60mg, 120mg subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo subcutaneous injection
Study: NCT01980927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NUCCA atlas correction
Description: A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine.
Study: NCT03688451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intrathecal administration over 3-5 minutes
Study: NCT04512859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Stellate ganglion block under ultra-guide will be administered using 0.25% ropivacaine 10mL

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stellate ganglion block under ultra-guide will be administered using 0.9% saline 10mL
Study: NCT00610740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical gemcitabine hydrochloride
Description: Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: hysterectomy
Study: NCT02861469

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: individual semi-structured interviews with general practitioners and family members

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: individual semi-structured interviews with general practitioners and family members
Study: NCT04007250

Intervention type: DEVICE
Intervention: FENIX™ Continence Restoration System
Description: The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~* FENIX™ System Implant~* FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed.
Study: NCT02940184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet Sitagliptin 100mg (evening before and morning of experiments)
Description: On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intestinal Fructose administration
Description: On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intestinal Fructose administration
Description: On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
Study: NCT03007043

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample
Study: NCT02008877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
Study: NCT02142296

Intervention type: DRUG
Group type: OTHER
Intervention: Eylea
Description: monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
Study: NCT03885063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benjamin Rose Institute Care Consultation (BRI-CC)
Description: The BRI-CC is a telephone-based intervention designed for adults with chronic conditions and has been used in persons with dementia and their caregiver (CG). This assessment is guided by the use of assessment tools with domains that trigger specific and pertinent needs of the dyad such as relationship strain, depression, financial concerns, memory problems, and difficult behaviors. To address unmet needs, the care consultant and dyad develop action plans with specific action steps pertinent to the dyad. The intervention involves maintenance and support where the care consultant (CC) continues the relationship with the dyad through regular telephone contact, email and mail. CC use a web-based reporting system, to maintain and track dyad information, assessments, action plans, completed tasks, and ongoing contacts. At a minimum, the care consultant will contact the dyad by telephone once per month over the duration of the study period (i.e. 6 months).
Study: NCT01740232

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trephination
Description: Artroscopic meniskal repair with trephination.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal meniscal repair
Description: Artroscopic meniskal repair without trephination.
Study: NCT00914901

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled salmeterol
Description: Inhalation of 100 micrograms salmeterol in one dose.

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled salmeterol
Description: Inhalation of 100 micrograms salmeterol in one dose.

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled salmeterol
Description: Inhalation of 100 micrograms salmeterol in one dose.
Study: NCT02062853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Group
Description: Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Group
Description: The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.